Aurobindo Pharma News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Aurobindo Pharma Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Aurobindo Pharma Ltd.
Rating: 5
Author: Motilal Oswal

Keep track of all breaking news and updates on Aurobindo Pharma from all sources in a single place.

Aurobindo Pharma Ltd.

27 Dec 2025, 11:54AM

1206.20

-0.43%

Company Update

Aurobindo Pharma Ltd - 524804 - Curateq Biologics Private Limited, A Wholly Owned Subsidiary Of The …

BSE India

This is to inform that Curateq Biologics Private Limited a wholly owned subsidiary of the Company has mutually agreed to terminate its agreement with BioFactura Inc., USA.

pdf

Aurobindo Pharma Ltd.

24 Dec 2025

1206.20

-0.43%

SAST

Aurobindo Pharma Ltd - 524804 - Closure of Trading Window

BSE India

Intimation of closure of trading window

pdf

Aurobindo Pharma Ltd.

23 Dec 2025

1206.20

-0.43%

Company Update

Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Acquisition

BSE India

Intimation of acquisition of additional 20% stake in Luoxin Aurovitas (Chengudu) Co.Ltd, China, a Joint Venture company.

pdf

Aurobindo Pharma Ltd.

18 Dec 2025

1206.20

-0.43%

Aurobindo Pharma's Andhra Arm Gets Form 483 With Five Observations From USFDA

NDTV Profit

The USFDA inspected the unit from December 8 to December 17, 2025, the Hyderabad-based drug firm said in a regulatory filing.

Aurobindo Pharma Ltd. is trading above its 200 day SMA of 1141.0

Aurobindo Pharma Ltd.

18 Dec 2025

1206.20

-0.43%

Company Update

Aurobindo Pharma Ltd - 524804 - Completion Of US FDA Inspection At Unit-IV Of APL Healthcare …

BSE India

Intimation of completion of US FDA inspection at Unit-IV of APL Healthcare Limited Limited, a wholly owned subsidiary of the Company.

pdf

Aurobindo Pharma Ltd.

15 Dec 2025

1206.20

-0.43%

Company Update

Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Intimation of investor meet.

pdf

Aurobindo Pharma Ltd.

12 Dec 2025

1206.20

-0.43%

Company Update

Aurobindo Pharma Ltd - 524804 - Completion Of US FDA Inspection At Unit-V Of Apitoria Pharma …

BSE India

Intimation of completion of US FDA inspection at Unit-V of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.

pdf

Aurobindo Pharma Ltd.

04 Dec 2025

1206.20

-0.43%

Aurobindo Pharma: Motilal Oswal Maintains 'Buy' Citing Multiple Growth Triggers, Sees Upto 18% Upside

NDTV Profit

Aurobindo Pharma's diversification and policy tailwinds signal potential upside, says Motilal Oswal, retaining 'Buy' call.

Aurobindo Pharma Ltd. has an average target of 1349.22 from 9 brokers.

Motilal Oswal retains 'Buy' on Aurobindo Pharma as FY26-28 prospects shine

Business Standard | 04 Dec 2025

Aurobindo Pharma Ltd.

03 Dec 2025

1206.20

-0.43%

Broad-based growth momentum building up

Buy: Aurobindo Pharma Ltd.

Target

Motilal Oswal

With considerable investment (INR35b) done till date by Aurobindo Pharma (ARBP) in the Pen-G/6-APA project and support from the government under the PLI scheme, ARBP is scaling up the production to enhance self-sufficiency of India in bulk drugs/intermediates to be used for Beta-Lactum antibiotics.